Production (Stage)
Cellectar Biosciences, Inc.
CLRB
$0.3822
-$0.031-7.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -6.60M | -2.36M | -14.66M | -919.40K | -26.64M |
| Total Depreciation and Amortization | 56.30K | 68.60K | 68.60K | 66.00K | 88.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 920.70K | -8.56M | 3.21M | -11.64M | 15.43M |
| Change in Net Operating Assets | -3.76M | -63.60K | 2.22M | -1.65M | -2.24M |
| Cash from Operations | -9.38M | -10.91M | -9.17M | -14.14M | -13.36M |
| Capital Expenditure | -- | -61.30K | 0.00 | -21.30K | -21.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -61.30K | 0.00 | -21.30K | -21.60K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 0.00 | 17.56M | 0.00 | 43.85M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 0.00 | 17.56M | 0.00 | 43.85M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.38M | -10.97M | 8.39M | -14.16M | 30.47M |